Southern California Research Center | Coronado, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Full description
The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study has its own hypotheses and outcome measures that will be assessed independently.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before randomization
Has moderately to severely active UC
Weight ≥40 kg
Satisfies at least 1 of the following criteria:
Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable
Adolescent participants ≥16 and <18 years of age can participate if approved by the country or regulatory/health authority
Participant assigned male sex at birth, if capable of producing sperm, agrees to abstain from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent; or uses prescribed contraception unless azoospermic
A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding and Is not a participant of childbearing potential (POCBP); or is a POCBP and uses an acceptable contraceptive method, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention, medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,020 participants in 11 patient groups, including a placebo group
Loading...
Central trial contact
Toll Free Number
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal